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Abstract
Background: Social impairment is a defining feature of autism spectrum disorder (ASD) with no demonstrated
effective pharmacologic treatments. The goal of this study was to evaluate efficacy, safety, and tolerability of
oral N-acetylcysteine (NAC), an antioxidant whose function overlaps with proposed mechanisms of ASD
pathophysiology, targeting core social impairment in youth with ASD.
Methods: This study was a 12-week randomized, double-blind, placebo-controlled trial of oral NAC in youth
with ASD. Study participants were medically healthy youth age 4 to 12 years with ASD, weighing ≥15 kg, and judged
to be moderately ill based on the Clinical Global Impressions Severity scale. The participants were randomized via
computer to active drug or placebo in a 1:1 ratio, with the target dose of NAC being 60 mg/kg/day in three divided
doses. The primary outcome measure of efficacy was the Clinical Global Impressions Improvement (CGI-I) scale
anchored to core social impairment. To investigate the impact of NAC on oxidative stress markers in peripheral
blood, venous blood samples were collected at screen and week 12.
Results: Thirty-one patients were enrolled (NAC = 16, placebo = 15). Three participants were lost to follow-up,
and three left the trial due to adverse effects. The average daily dose of NAC at week 12 was 56.2 mg/kg (SD = 9.7) with
dose ranging from 33.6 to 64.3 mg/kg. The frequency of adverse events was so low that comparisons between
groups could not be conducted. At week 12, there was no statistically significant difference between the NAC
and placebo groups on the CGI-I (p > 0.69) but the glutathione (GSH) level in blood was significantly higher in
the NAC group (p < 0.05). The oxidative glutathione disulfide (GSSG) level increased in the NAC group, however
only at a trend level of significance (p = 0.09). There was no significant difference between the NAC and placebo
groups in the GSH/GSSG ratio, DNA strand break and oxidative damage, and blood homocysteine levels at week
12 (ps > 0.16).
Conclusions: The results of this trial indicate that NAC treatment was well tolerated, had the expected effect of
boosting GSH production, but had no significant impact on social impairment in youth with ASD.
Trial registration: Clinicaltrails.gov NCT00453180
Keywords: Autism, Autism spectrum disorder, Social impairment, N-acetylcysteine, Oxidative stress
* Correspondence: Craig.erickson@cchmc.org
1Cincinnati Children’s Hospital Medical Center, University of Cincinnati
College of Medicine, 3333 Burnet Avenue MLC 4002, Cincinnati, OH 45229,
USA
Full list of author information is available at the end of the article
© 2016 Wink et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wink et al. Molecular Autism  (2016) 7:26 
DOI 10.1186/s13229-016-0088-6
Background
Social and communication impairments are the defining
features and key predictors of long-term outcome in aut-
ism spectrum disorder (ASD) [1, 2]. To date, no medica-
tion has demonstrated significant impact on these core
deficits in controlled trials. In 2014, the United States
Center for Disease Control reported that one in 68 chil-
dren in the USA is diagnosed with ASD, highlighting the
critical need for targeted treatment development in this
disorder [3]. Growing neurobiologic understanding of
ASD has identified glutamatergic neurotransmission and
metabolic pathways impacting oxidative stress levels as
potential targets of drug development in this complex
disorder [4]. Glutamatergic dysfunction appears to play a
significant role in ASD pathology, as studies have identi-
fied abnormal peripheral glutamate levels, aberrant glu-
tamate expression in the postmortem brain, and genetic
abnormalities in glutamate signaling genes in individuals
with ASD [5]. Excessive oxidative stress also has been
identified as playing a potential role in ASD pathophysi-
ology. Increased peripheral oxidative biomarkers, evidence
of oxidative stress in the postmortem brain, and abnor-
malities in genes encoding for antioxidant enzymes have
been reported in individuals with ASD [4, 6, 7].
N-acetylcysteine (NAC) is a unique antioxidant whose
function overlaps with both the glutamatergic and oxi-
dative stress hypotheses proposed to contribute to the
pathophysiology of ASD. NAC is the N-acetyl derivative of
L-cysteine used for decades in treatment of acetaminophen
overdose, as a mucolytic in chronic obstructive pulmonary
disease, and as a renal protectant in contrast-induced ne-
phropathy [8]. NAC is rapidly absorbed via oral dosing,
though total oral bioavailability of NAC is quite low (~9 %)
[9]. NAC crosses the blood-brain barrier (BBB), though its
efficiency may depend upon dose, administration, and for-
mulation [10]. In the brain, NAC is oxidized from L-cyst-
eine to cystine which is ultimately involved in regulation of
extracellular glutamate levels [11]. NAC is cell membrane
permeable and is reduced to cysteine intracellularly, which
is a key component of the antioxidant glutathione (GSH)
[10]. NAC’s involvement in both extracellular glutamate
modulation and intracellular restoration of antioxidant
GSH levels, coupled to its long history of human safety
data, make NAC an intriguing substance in ASD-targeted
treatment development.
Placebo-controlled studies of NAC in ASD have previ-
ously focused on treatment of ASD-associated irritability
marked by physical aggression, self-injurious behavior,
and severe tantrums. A pilot placebo-controlled study by
Hardan et al. (2012) demonstrated a significant reduction
in irritability symptoms as measured by the Aberrant Be-
havior Checklist Irritability subscale [12] (ABC-I) in 29
youth aged 3.2–10.7 years with ASD [13]. Additionally, two
small double-blind, placebo-controlled studies of NAC in
conjunction with risperidone for treatment of irritability in
youth with ASD also showed a significant reduction in
ABC-I subscale scores in the NAC-treated groups [14, 15].
Furthermore, case studies have demonstrated improvement
of core ASD features including social communication and
repetitive behaviors with NAC treatment; however, this ef-
fect has not been confirmed in controlled trials [16, 17].
To date, no study of NAC in ASD has evaluated the
impact of NAC on markers of oxidative stress in periph-
eral blood. Individuals with ASD are believed to have de-
creased total GSH levels and elevated levels of oxidative
glutathione disulfide (GSSG) [4]. These abnormalities
lead to a reduction in the ratio of active GSH to inactive
GSSH resulting in increased intracellular oxidative stress
which may impact on individual’s capacity to maintain
cellular methylation and increase vulnerability to oxida-
tive damage [18]. This change has the potential to de-
crease an individual’s ability to resist infection, resolve
inflammation, and respond to environmental exposures.
Correction of these abnormalities with NAC treatment
could have substantial impact on the health of individuals
with ASD.
The goal of this randomized, double-blind, placebo-
controlled pilot study of NAC in youth with ASD was to
evaluate the efficacy of oral NAC targeting core social
impairment of ASD and evaluate the safety and tolerability
of NAC in this population. Additionally, this project incor-
porated measures of oxidative stress that may be impacted
by NAC treatment, including measures of pre- and post-
treatment peripheral whole blood levels of GSH and
GSSG. We hypothesized that treatment with NAC in this
population would result in improvement in core social
impairment of ASD as measured by the Clinical Global
Impression Improvement (CGI-I) scale [19], and that
NAC treatment would result in increased GSH and
GSSH levels.
Methods
Study design
This study was a 12-week randomized, double-blind,
placebo-controlled pilot trial of oral NAC in youth with
ASD. The study was conducted at Indiana University
School of Medicine (IUSM) between December 2006
and November 2009. The study was approved by the
IUSM institutional review board. Guardians of all partic-
ipants provided written informed consent prior to study
enrollment. Assent was obtained from enrolled youth
when possible.
Study participants were youth ages 4 to 12 years with
a diagnosis of autistic disorder, Asperger’s disorder, or
pervasive developmental disorder not otherwise specified
(PDD NOS). Subjects with known genetic syndromes asso-
ciated with autism were excluded (for example, fragile X
syndrome, tuberous sclerosis). Participants were diagnosed
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via clinical interview completed by study physician with ex-
pertise in ASD (DJP, CJM, CAE), based on the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) [20] diagnostic criteria, and corroborated by ad-
ministration of the Autism Diagnostic Interview-Revised
[21] (ADI-R). Participants diagnosed with PDD NOS dem-
onstrated pervasive impairment in social interaction and/or
communication skills as well as stereotyped behaviors and
restricted interests, but did not meet full criteria for diagno-
sis of autistic disorder or Asperger’s disorder. All partici-
pants weighed ≥15 kg and were medically healthy based on
physical exam and review of medical history completed by
study physicians. Participants were judged by study
physician as being at least “moderately ill” as measured
by the Clinical Global Impression Severity [19] (CGI-S)
scale rating at baseline. The CGI-S is a clinician-rated
global assessment of symptom severity scale ranging
from 1 to 7 (1 = normal, not at all ill; 2 = borderline ill;
3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 =
severely ill; 7 = among the most extremely ill patients).
Concomitant medications were permitted if doses were
stable for at least 60 days prior to study initiation and
remained stable throughout the study. Participants taking
known glutamatergic modulators such as dextrome-
thorphan, D-cycloserine, amantadine, memantine, lamo-
trigine, or riluzole were excluded. Patients taking daily
acetaminophen, daily nonsteroidal anti-inflammatory
medications, daily antioxidant medications such as
high-dose vitamin supplements, and medications with
known drug-interactions (i.e., carbamazepine) within
30 days of baseline were also excluded. Subjects were
required to be able to swallow capsules. Potential subjects
with profound cognitive impairment (mental functioning
below 18 months of age) as measured by the Leiter Inter-
national Test of Intelligence-Revised [22] were excluded.
Following screening and baseline measures, partici-
pants were randomized 1:1 via computer—by the inves-
tigational pharmacy. All participants, guardians, and
investigators remained blind to study assignment. NAC
and matching placebo were prepared by CustomMed
Apothecary. Participants randomized to active drug were
administered capsules containing 300 or 600 mg of NAC,
with a target dose of 60 mg/kg/day in three divided doses
and a maximum dose of 4200 mg/day. Patients weighing
15 to 30 kg began treatment with a starting dose of
300 mg/day; those weighing above 30 kg started with
600 mg/day. Patients were required to tolerate a minimum
dose of 300 mg/day to continue in the trial. Dose was ti-
trated to the target dose over the first 3 weeks of study
participation. Dose then remained stable for all subjects in
the last 9 weeks of the study, although reductions due to
adverse effects were permitted at any time. Subjects were
evaluated in person at screen and baseline, by phone at
week 2, and in person at weeks 4, 8, and 12. Assessment
for adverse effects was completed during each interaction.
Vital signs including height, weight, blood pressure, and
heart rate were measured at every in-person study visit.
Safety labs including complete blood cell count (CBC) and
comprehensive metabolic panel (CMP) were collected at
screen and week 12.
The primary outcome measure of efficacy was the
CGI-I scale anchored to study physician (DJP, CJM,
CAE) assessment of core social impairment considering
the individuals’ overall level of cognitive, adaptive, and
social functioning. The CGI-I is a clinician-rated global
assessment of symptom change rated on a scale from 1
to 7 (1 = very much improved; 2 = much improved; 3 =
minimally improved; 4 = no change; 5 = minimally
worse; 6 = much worse; 7 = very much worse). In this
study, a positive response to NAC treatment was defined
as scoring a 1 “very much improved “or 2 “much im-
proved” on the CGI-I. Study physicians completed annual
CGI training to ensure internal consistency with this out-
come measure. Secondary outcome measures included the
CGI-S, ABC, Social Responsiveness Scale [23] (SRS) raw
score, and Vineland Adaptive Behavior Scales 2nd Edition
[24] (VABS-II) survey edition raw score. The SRS is a
standardized, caregiver reported measure of the core
symptoms of ASD [23]. The ABC is a parent questionnaire
measuring five behavioral domains including irritability, so-
cial withdrawal, stereotypy, hyperactivity, and inappropriate
speech [12]. The VABS-II is a semi-structured caregiver
interview which provides a measure of an individual’s over-
all adaptive functioning [24]. All measures have been used
extensively in ASD research [25–27]. The CGI-I was com-
pleted at weeks 4, 8, and 12. The ABC and SRS were com-
pleted at baseline and weeks 4, 8, and 12. The CGI-S and
VABS-II were completed only at baseline and week 12.
Early morning, fasting, venous blood samples for
measurement of oxidative stress biomarkers GSH, GSSH,
total homocysteine, strand breakage, and oxidative DNA
damage were collected in EDTA containing Vacutainers at
screen and week 12.
Measurement of reduced and oxidized glutathione
Concentrations of reduced and oxidized glutathione
(GSH and GSSG) in whole blood samples were analyzed
simultaneously using HPLC-electrochemical detection as
described previously [28]. Briefly, 1 ml of blood sample
was added to 0.5 ml precipitating solution containing
0.2 M perchloric acid and 100 μM EDTA, and vortexed
briefly. After incubation at room temperature for 45 min,
samples were centrifuged at 10,000g for 3 minutes. The
resulting supernatants were filtered and injected into
high-performance liquid chromatography (HPLC; Waters
2690) for analysis immediately or frozen in liquid nitrogen
and stored at −80 °C before analysis. The separation of
analytes was achieved on a reverse phase Symmetry C-18
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column (5 μm, 150 × 4.6 mm; Waters). GSH and GSSG
were detected using an ESA Coulochem II (ESA Inc.
Chelmsford, MA) equipped with a guard cell. The potential
settings for the detector were E1 450 mV, E2 900 mV, and
guard cell 1000 mV. The amount of GSH and GSSG was
calculated from the respective calibration curves, and the
ratio of GSH/GSSG for each sample was also calculated.
Measurement of blood homocysteine
Total homocysteine in whole blood sample was deter-
mined using an HPLC method as described previously
with minor modifications [29, 30]. Briefly, 1 ml EDTA
blood samples were lysed by vigorously shaking for at
least 10 s after adding 10 μl Nonidet P40 (pure) and
10 μl citric acid monohydrate (2.5 M). The lysates were
then centrifuged at 10,000g for 3 minutes at room
temperature. Following reduction of the sample with tri-
n-butylphosphine, precipitation of protein with perchloric
acid and derivatization with ammonium 7-fluorobenzo-2-
oxa-1,3-diazole-4-sulfonate, the samples were then analyzed
using reversed-phase high-performance liquid chromatog-
raphy (Waters Alliance 2695 separation module) followed
by fluorescence detection (Waters 474 fluorescence
detector) (Waters Corporation, Milford, MA).
Direct and oxidative DNA damage: comet assay
Immediately after blood collection, whole blood (10 μl)
was mixed with 0.5 ml RPMI 1640 containing 10 % FBS,
10 % DMSO, 1 mM deferoxamine, step-frozen and
stored at −80 °C until analysis. The comet assay was per-
formed as described previously [31, 32]. Briefly, 6 μl of
blood was mixed with 70 μl 1 % low-melting-point agarose
and applied onto comet slides (Trevigen Inc, Gaithersburg,
MD). Cells were lysed, placed in alkali buffer, and then elec-
trophoresed. Slides were stained with ethidium bromide,
and 100 randomly selected nuclei/sample were evaluated
(Komet 5.5; Kinetic Imaging Ltd., Liverpool, UK). For the
assessment of oxidative DNA damage, a modified alkaline
comet assay was performed that included enzymatic
digestion with formamidopyrimidine-DNA glycosylase
(fpg) prior to electrophoresis. DNA damage was expressed
as Comet (Olive) tail moment [(tail mean − head mean) ×
tail%DNA/100].
Statistical analysis
Our sample size (goal 32 participants) was chosen based
on recommendation for sampling in pilot studies where
little is known about treatment response rates [33].
Baseline demographic data including age, sex, race, level
of intellectual quotient (IQ), ASD diagnostic sub-type,
concomitant medications, and clinical ratings (CGI-S,
ABC, SRS, and VABS-II scores) was compiled, and means
and percentages were calculated to describe the NAC and
placebo groups. Baseline demographic differences between
groups were tested using chi-square tests (categorical data)
and independent sample t test (continuous data) using a
two-tailed p value of 0.05 for the alpha.
For the CGI-I primary outcome measure, differences
between the two treatment groups were tested at weeks
4, 8, 12 using chi-square tests. For the CGI-S secondary
outcome measure, a chi-square test was employed to
examine change from baseline to week 12 by creating
two CGI-S categories: (1) those subjects whose severity
score decreased (i.e., clinically improved) by at least one
point from baseline to week 12 and (2) those subjects
whose scores remained the same during the same
period. For the ABC, SRS, VABS-II, and oxidative stress
biomarkers, differences between the groups for change
in each outcome measure over the course of the study
were tested using multi-level modeling (i.e., we exam-
ined if there were differences between the two groups in
terms of change in the outcome scores over the course
of the study). For each outcome, time was modeled at
level-one as a random effect with treatment group en-
tered as a level-two fixed effect. The cross-level inter-
action between group and time tested the differences
between the two groups in the change over time using
maximum likelihood estimation with robust standard er-
rors with Mplus 5.21 [34] (baseline, week 4, week 8, and
week 12 data was used for the ABC and SRS; baseline
and week 12 data was used for the VABS-II and oxidative
stress biomarkers). Since there is no method to directly
calculate the effect size of the between-subject effects on
the within-subject effects for multilevel modeling, we cal-
culated an effect size of the difference between the groups
on the mean differences between baseline and week 12 for
the groups. Specifically, a Cohen’s d was calculated by sub-
tracting the mean score at week 12 from the score at base-
line for each group, and a difference score was calculated
by subtracting the change scores between the groups. This
difference score was then divided by the pooled standard
deviation of the change scores. Independent sample t tests
were used to compare the levels of oxidative markers be-
tween NAC and placebo groups at baseline and week 12.
For all types of tests, a one-tailed p value of 0.05 was used
as the alpha. A one-tailed test was used based on the a
priori hypothesis that the NAC group would have greater
change in clinical ratings and oxidative stress markers over
the course of the study than the placebo group. We did
not correct for multiple comparisons given the pilot na-
ture of the work.
Adverse event data was compiled to describe the NAC
and placebo groups. Separate analyses were conducted
for the vital sign measurements, CMP, and CBC employ-
ing the same method as the treatment analyses, though
only two time points, screen and week 12, were evaluated.
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Results
Thirty-one participants initially enrolled in the trial;
however, six participants did not complete the study.
Three participants were lost to follow-up after week 4
(two NAC and one placebo), and three withdrew due to
irritability (NAC), diarrhea and encopresis (placebo), and
defiant and self-injurious behavior (placebo), respect-
ively. At baseline, data for all 31 enrolled subjects was
employed in the analysis. Post-baseline, only data for the
25 completers was analyzed, as there is no method for
imputing data for multi-level models.
At baseline, participants ranged in age from 4 to
12 years. The average age was 7.6 years (SD = 2.5, n = 16)
for the NAC group and 8.2 years (SD = 2.9, n = 15) for
the placebo group (Table 1). The majority of the partici-
pants were male (>75 %), white (>90 %), and had an IQ
above 85. For the NAC group, the ASD diagnostic
sub-types were primarily autistic disorder (43.8 %) and
PDD-NOS (43.8 %) while the placebo group included
primarily those with autistic disorder (46.7 %) and
Asperger’s disorder (33.3 %). On the CGI-S scale, the
majority of the participants in both groups (>85 %)
were rated as either 5 “markedly” or 6 “severely ill”. There
was no statistically significant baseline difference between
groups for any clinical ratings (ABC, SRS, VABS-II), with
the exception of a trend toward significantly higher score
on the ABC stereotypy subscale in the placebo group
(t value = 1.85, 0.07; NAC M = 4.75, SD = 3.3; placebo
M = 7.00, SD = 4.9). Additionally, there was no signifi-
cant difference in type or number of baseline con-
comitant medications between groups (all ps > 0.11).
The average daily dose of NAC at week 12 was
56.2 mg/kg (SD = 9.7) with dose ranging from 33.6 to
64.3 mg/kg. Overall, NAC was well tolerated by study
participants. The majority of adverse events occurred
only once, and the frequency of adverse events was so
low that comparisons between groups could not be con-
ducted (Table 2). Overall, upper respiratory symptoms
were the most commonly reported event for both groups
(NAC n = 10, 62.5 %; placebo n = 6, 40.0 %). The next
Table 1 Demographic data and baseline characteristics
Groups Test of differences
NAC Placebo
Characteristics n/total % n/total % Chi-squarea
Gender—male 12/16 75.0 12/15 80.0 0.11
Race—White 16/16 100.0 14/15 93.3 1.01
Diagnosis
Autistic disorder 7/16 43.8 7/15 46.7 0.03
Asperger’s disorder 2/16 12.5 5/15 33.3 1.92
PDD-NOS 7/15 43.8 3/15 20.0 1.98
CGI-S
Marked (5) 6/16 37.5 9/15 60.0 1.57
Severe (6) 9/16 56.3 6/15 40.0 0.82
Extreme (7) 1/16 6.3 0/15 0.0 0.97
Concomitant medication (y/n) 6/16 37.5 10/15 66.7 2.64
Medication types
Psychostimulants 3/16 18.7 3/15 20.0 0.01
Alpha 2 agonists 1/16 6.2 2/15 13.3 0.44
Antipsychotics 4/15 25.0 5/15 33.3 0.26
Sleep aids 6/16 37.5 2/15 13.3 2.36
Antidepressants 1/16 6.2 3/15 20.0 1.30
Antiepileptic medication 2/16 12.5 0/15 0.0 2.01
Mean SD Mean SD t testb
Age 7.63 2.5 8.20 2.9 0.59
Full scale IQ 86.27 21.8 87.43 11.7 0.18
Number of concomitant medications per participant 1.20 1.8 0.94 1.0 0.51
aTwo-tailed significance +p < .10; *p < .05. No p values for these chi-squares reached significance at .05 and ranged from .11 to .87
bTwo-tailed significance +p < .10; *p < .05 and ps ranged from .56 to .94
NAC N-acetylcysteine, PDD-NOS pervasive developmental disorder not otherwise specified, CGI-S clinical global impression severity scale
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most frequent events were headaches (NAC n = 3, 18.7 %;
placebo n = 3, 20.0 %), stomachache (NAC n = 2, 12.5 %;
placebo n = 2, 13.3 %), and fever (NAC n = 3, 18.7 %; pla-
cebo n = 1, 6.7 %). The majority of reported adverse events
were mild, with only five (6.7 %) reported as moderate. No
severe adverse events were reported. There were no sig-
nificant differences found between the groups for changes
from screen to week 12 on vital signs or safety lab values
(all p > 0.10).
Primary and secondary outcomes
There was no statistically significant difference between
the NAC and the placebo groups at week 4 (p > 0.60),
week 8 (p > 0.79), or week 12 (p > 0.69) on the CGI-I pri-
mary outcome measure (Table 3). At each time period,
at least half of all participants (≥50 %) were rated as hav-
ing no change. On the CGI-S secondary outcome meas-
ure, no participants were noted to have increased scores
suggesting clinical worsening of symptoms. There were
also no differences between the NAC and placebo
groups for those whose severity scores decreased from
baseline to week 12 (χ2 = 0.43, p = 0.40; NAC 46.2 %, n = 6;
placebo 33.3 %, n = 4). On the ABC, SRS, and VABS-II
secondary outcome measures, the employed models found
no significant differences between groups in change from
baseline to week 12 (all ps > 0.13 (Table 4)). Using the cut-
off of a Cohen’s d of 0.25 for small, 0.50 for medium, and
0.80 for large, 100 % of the effects were ≤ the small effect
size [35]. For all of the models that had a small effect size,
the placebo group consistently had the larger average de-
crease in score.
Oxidative stress biomarkers
Baseline (pre-treatment) levels of the oxidative markers
including GSH, GSSG, GSH/GSSG ratio, DNA strand
break and oxidative damage, and blood homocysteine
were not significantly different between the NAC and
placebo groups (p > 0.05 for all). At week 12, the GSH
level in blood was significantly higher in the NAC group
compared to placebo (780.3 vs. 640.4 μM; p < 0.05,
Table 4). The GSSG level increased in the NAC treat-
ment group, however with only marginal significance in
comparison with the placebo group (16.7 vs. 12.5 μM; p
= 0.09, Table 4). Using the Cohen’s d cutoff employed
above for effect sizes, the size of the differences for the
significant and the marginally significant effects were
large- and medium-sized effects, respectively. For the
GSH/GSSG ratio, strand break and oxidative damage of
DNA, as well as blood homocysteine, there were no
significant differences between the NAC and placebo
groups from baseline to week 12 (ps > 0.16).
Discussion
This study was designed to evaluate the safety and effi-
cacy of NAC targeting core social impairment in youth
with ASD. The results of this randomized, placebo-
controlled trial indicate that NAC treatment was well
tolerated by study participants, had the expected effect
of boosting GSH production in peripheral blood, but
had no significant impact on the core social impairment
Table 2 Frequency of adverse effects
NAC (n = 16) Placebo (n = 15)
Adverse effects Mild Mod Severe Mild Mod Severe
URI 9 1 0 5 1 0
Headache 3 0 0 2 1 0
Stomachache 2 0 0 2 0 0
Fever 2 1 0 0 0 0
Irritability 2 0 0 1 0 0
Insomnia 2 0 0 0 0 0
Otitis media 1 1 0 1 0 0
Increased enuresis 1 0 0 1 0 0
Interrupted sleep 1 0 0 1 0 0
Localized rash 1 0 0 1 0 0
Nausea 1 0 0 1 0 0
Stereotypy 0 0 0 2 0 0
The table only lists adverse effects occurring ≥2 times across the samples
Placebo group reported one moderate case of the following adverse effects:
defiant behavior, hives, itchy skin, and threats to hurt self
Placebo group reported one mild case of the following adverse effects:
accidental injury (arm), constipation, diarrhea, dry mouth, emotional outburst,
encopresis, increased hyperactivity, self-injurious behavior (skin picking), sinus
infection, skin infection, sore throat, urinary tract infection, and weight gain
NAC group reported one mild case of the following adverse effects:
aggression, appetite increase, behavior worse, change in speech, early
morning awakening, edema, medical or surgical procedure, swollen neck/
lymph nodes, and tic
NAC N-acetylcysteine, Mod moderate, URI upper respiratory infection
Table 3 Clinical Global Impression-Improvement scale score,
NAC vs. placebo
Groups Test of
differencesNAC Placebo
n/total % n/total % Chi-squarea
Week 4 0.28
Response 4/15 26.7 5/14 35.7
No response 11/15 73.3 9/14 64.3
Week 8 0.07
Response 5/13 38.5 4/12 33.3
No response 8/13 61.5 8/12 66.7
Week 12 0.15
Response 6/12 50.0 5/11 45.5
No response 6/12 50.0 6/11 54.5
aOne-tailed significance +p < .10; *p < .05. No p values for these chi-squares
reached significance at .05 and ranged from .60 to .79
Response = very much improved (1) or much improved (2); no response =
minimally improved (3), no change (4), minimally worse (5); no participants
scored much worse (6) or very much worse (7)
NAC N-acetylcysteine
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of ASD when compared to placebo treatment. The re-
sults of this study do not support the use of NAC for
treatment of core social impairment of ASD, though the
health impact of the resultant increase on GSH remains
unclear. In addition, the study did not note other behav-
ioral improvements with NAC use such as the reduction
in irritability reported by Harden et al. (2012) [13].
Interpretation of these results must be taken in con-
text of the study’s limitations. Participant diagnoses were
made by study physicians with expertise in ASD corrob-
orated by the ADI-R similar to methods employed in
other ASD drug studies [36]. Nevertheless, administration
of a research reliable Autism Diagnostic Observation
Schedule would have added to the validity of diagnoses in
this study. Furthermore, limitation of the study to just par-
ticipants with diagnosis of autistic disorder would have
lessened the heterogeneity of our sample. Our study popu-
lation was potentially biased toward individuals with
higher level of functioning, as the majority of participants
had IQ above 85. This limits the generalizability of these
study results to the broader population of individuals with
ASD. This higher functioning study population may have
also contributed to lack of improvement in irritability
noted in this study. The baseline ABC-I of study partic-
ipants was 17.0 (SD 11.8) in the NAC group and 18.3
(SD 9.2) in the placebo group, which is slightly below
the standard cutoff ABC-I score of 18 used in drug
studies targeting ASD-associated irritability [36]. How-
ever, the baseline ABC-I scores in our study are higher
than those in the Hardan study which demonstrated
improvement irritability with NAC treatment [13], so
the impact this had on our study outcome is unclear.
Additionally, the small sample size combined with the
inherent significant placebo response rates in ASD core
symptom trials enhances type II error potential thus
rendering the project potentially underpowered to detect
meaningful change. The small sample size also reduces
the ability to effectively correlate treatment response with
baseline oxidative stress markers or with change in such
markers with treatment.
Table 4 Means, standard deviations, and differences in change scores between NAC and Placebo groups
NAC Placebo
Baseline 12 Weeks Baseline 12 Weeks Group with largest
changeb
Cohen’s d
M SD M SD M SD M SD z testa
ABC
Hyperactivity 20.6 12.4 17.4 16.4 22.6 10.5 15.1 10.8 1.04 PLB 0.34
Speech 3.9 2.8 4.1 3.9 5.7 2.9 5.14 3.5 0.66 PLB 0.24
Irritability 17.0 11.8 14.9 14.0 18.3 9.2 12.0 7.3 1.09 PLB 0.40
Lethargy 13.8 8.1 10.0 7.1 14.0 10.5 7.9 4.7 1.15 PLB 0.31
Stereotypy 4.8 3.3 3.9 5.1 7.0 4.9 5.8 4.0 0.56 PLB 0.09
SRS
Total score 108.5 20.7 85.8 34.9 109.1 16.5 89.1 26.3 0.32 NAC 0.11
VABS-II
Comm 85.9 32.1 88.5 32.5 89.4 32.2 95.0 30.3 0.85 PLB 0.09
Daily Liv. Sk. 93.1 33.7 99.0 37.1 87.6 28.1 98.6 33.4 0.17 PLB 0.16
Socialization 66.8 18.8 71.7 18.7 68.3 20.7 75.9 21.0 0.87 PLB 0.14
Composite 61.3 19.4 62.9 17.1 53.6 15.1 60.5 18.8 1.08 PLB 0.30
Levels in whole blood (uM)
GSH 484.8 212.7 780.3 220.6 474.5 191.6 640.4 190.9 1.74* NAC 0.64
GSSG 12.0 2.5 16.7 10.5 12.8 5.0 12.5 4.4 1.37+ NAC 0.88
GSH/GSSG 43.4 25.6 53.5 16.8 45.2 31.8 59.6 27.0 0.34 PLB 0.17
Homocysteine 4.3 6.1 9.9 13.7 1.9 1.2 5.6 6.8 0.41 NAC 0.27
DNA damage
DNA strand breakage 0.7 0.1 0.7 0.3 0.6 0.2 0.6 0.1 0.38 EVEN 0.00
Oxidative DNA damage 0.9 0.2 1.2 0.4 1.1 0.5 1.2 0.6 0.95 NAC 0.45
aOne-tailed significance +p < .10; *p < .05. Z test of the effect of between level variable of group on the within-level variable of time testing if the change from
baseline to week 12 is different between groups. No one-tailed p values for these z tests reached significance at .05 and ranged from .13 to .50
bIdentifies which group had the largest change from baseline to week 12
NAC N-acetylcysteine, M mean, SD standard deviation, ABC Aberrant Behavior Checklist, PLB placebo, SRS social responsiveness scale, VABS-II Vineland adaptive
behavior scale 2nd edition, Comm communication, Liv. Sk. living skills, GSH glutathione, GSSG oxidative glutathione disulfide
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The NAC formulation employed in this study was a
powder which was encapsulated by the investigative
pharmacy and stored under normal pharmacy conditions.
No studies of impurity were completed on this compound,
and no analyses were completed to assess its stability.
Furthermore, this packaging was different than the
method employed by Hardan et al. (2012) who utilized
an individual foil packaging method to protect the in-
tegrity of the active ingredient against oxidation [13].
While this difference could have in theory reduced the
potency of our formulation, the biologic impact of our
treatment was clear given the significant NAC-associated
increase in GSH levels at week 12. It is unclear; however, if
the change in oxidative markers and potential clinical
impact may have differed had we employed an individ-
ual foil packaging method. Further, whether an increase
in peripheral blood GSH levels, and the NAC formulation
employed in our study, translates to clinically significant
CNS antioxidant activity is unclear as there remains de-
bate in the field regarding the ability of NAC to efficiently
cross the BBB [10]. In future studies, alterations to NAC
formulation including esterification of the carboxyl group
producing N-acetylcysteine ethyl ester or creation of the
amide derivative N-acetylcysteine amide may increase this
medication’s oral bioavailability, BBB permeability, and
therefore therapeutic potential [10].
Conclusions
The results of this study suggest that NAC treatment does
not have significant impact on the core social impairment
of ASD. However, the small study size limits interpretation
of these results. Additional larger-scale study powered to
predict treatment response based on baseline peripheral
oxidative markers may be indicated. Future studies may
also wish to consider the use of a NAC formulation with
improved bioavailability and BBB permeability.
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